122 related articles for article (PubMed ID: 38701957)
1. AS1411 binds to nucleolin via its parallel structure and disrupts the exos-miRNA-27a-mediated reciprocal activation loop between glioma and astrocytes.
Sun X; Zhang W; Gou C; Wang X; Wang X; Shao X; Chen X; Chen Z
Biochim Biophys Acta Mol Basis Dis; 2024 Jun; 1870(5):167211. PubMed ID: 38701957
[TBL] [Abstract][Full Text] [Related]
2. AS1411-Induced Growth Inhibition of Glioma Cells by Up-Regulation of p53 and Down-Regulation of Bcl-2 and Akt1 via Nucleolin.
Cheng Y; Zhao G; Zhang S; Nigim F; Zhou G; Yu Z; Song Y; Chen Y; Li Y
PLoS One; 2016; 11(12):e0167094. PubMed ID: 27907160
[TBL] [Abstract][Full Text] [Related]
3. Nucleolin Overexpression Confers Increased Sensitivity to the Anti-Nucleolin Aptamer, AS1411.
Sharma VR; Thomas SD; Miller DM; Rezzoug F
Cancer Invest; 2018; 36(9-10):475-491. PubMed ID: 30396283
[TBL] [Abstract][Full Text] [Related]
4. Aptamer-based Targeted Delivery of a G-quadruplex Ligand in Cervical Cancer Cells.
Carvalho J; Paiva A; Cabral Campello MP; Paulo A; Mergny JL; Salgado GF; Queiroz JA; Cruz C
Sci Rep; 2019 May; 9(1):7945. PubMed ID: 31138870
[TBL] [Abstract][Full Text] [Related]
5. Plasma membrane nucleolin is a receptor for the anticancer aptamer AS1411 in MV4-11 leukemia cells.
Soundararajan S; Wang L; Sridharan V; Chen W; Courtenay-Luck N; Jones D; Spicer EK; Fernandes DJ
Mol Pharmacol; 2009 Nov; 76(5):984-91. PubMed ID: 19657047
[TBL] [Abstract][Full Text] [Related]
6. Mechanistic studies of anticancer aptamer AS1411 reveal a novel role for nucleolin in regulating Rac1 activation.
Reyes-Reyes EM; Šalipur FR; Shams M; Forsthoefel MK; Bates PJ
Mol Oncol; 2015 Aug; 9(7):1392-405. PubMed ID: 25911416
[TBL] [Abstract][Full Text] [Related]
7. A new paradigm for aptamer therapeutic AS1411 action: uptake by macropinocytosis and its stimulation by a nucleolin-dependent mechanism.
Reyes-Reyes EM; Teng Y; Bates PJ
Cancer Res; 2010 Nov; 70(21):8617-29. PubMed ID: 20861190
[TBL] [Abstract][Full Text] [Related]
8. Cell Surface Nucleolin as a Promising Receptor for Effective AS1411 Aptamer-Mediated Targeted Drug Delivery into Cancer Cells.
Mosafer J; Mokhtarzadeh A
Curr Drug Deliv; 2018; 15(9):1323-1329. PubMed ID: 30039760
[TBL] [Abstract][Full Text] [Related]
9. Modified AS1411 Aptamer Suppresses Hepatocellular Carcinoma by Up-Regulating Galectin-14.
Cho Y; Lee YB; Lee JH; Lee DH; Cho EJ; Yu SJ; Kim YJ; Kim JI; Im JH; Lee JH; Oh EJ; Yoon JH
PLoS One; 2016; 11(8):e0160822. PubMed ID: 27494117
[TBL] [Abstract][Full Text] [Related]
10. AS1411 Nucleolin-Specific Binding Aptamers Reduce Pathological Angiogenesis through Inhibition of Nucleolin Phosphorylation.
Iturriaga-Goyon E; Vivanco-Rojas O; Magaña-Guerrero FS; Buentello-Volante B; Castro-Salas I; Aguayo-Flores JE; Gracia-Mora I; Rivera-Huerta M; Sánchez-Bartés F; Garfias Y
Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884955
[TBL] [Abstract][Full Text] [Related]
11. AS1411 alters the localization of a complex containing protein arginine methyltransferase 5 and nucleolin.
Teng Y; Girvan AC; Casson LK; Pierce WM; Qian M; Thomas SD; Bates PJ
Cancer Res; 2007 Nov; 67(21):10491-500. PubMed ID: 17974993
[TBL] [Abstract][Full Text] [Related]
12. The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells.
Soundararajan S; Chen W; Spicer EK; Courtenay-Luck N; Fernandes DJ
Cancer Res; 2008 Apr; 68(7):2358-65. PubMed ID: 18381443
[TBL] [Abstract][Full Text] [Related]
13. AS1411 Aptamer/Hyaluronic Acid-Bifunctionalized Microemulsion Co-Loading Shikonin and Docetaxel for Enhanced Antiglioma Therapy.
Wang H; Zhu Z; Zhang G; Lin F; Liu Y; Zhang Y; Feng J; Chen W; Meng Q; Chen L
J Pharm Sci; 2019 Nov; 108(11):3684-3694. PubMed ID: 31465736
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic applications of AS1411 aptamer, an update review.
Yazdian-Robati R; Bayat P; Oroojalian F; Zargari M; Ramezani M; Taghdisi SM; Abnous K
Int J Biol Macromol; 2020 Jul; 155():1420-1431. PubMed ID: 31734366
[TBL] [Abstract][Full Text] [Related]
15. A nucleolin-targeted multimodal nanoparticle imaging probe for tracking cancer cells using an aptamer.
Hwang DW; Ko HY; Lee JH; Kang H; Ryu SH; Song IC; Lee DS; Kim S
J Nucl Med; 2010 Jan; 51(1):98-105. PubMed ID: 20008986
[TBL] [Abstract][Full Text] [Related]
16. G-quadruplex oligonucleotide AS1411 as a cancer-targeting agent: Uses and mechanisms.
Bates PJ; Reyes-Reyes EM; Malik MT; Murphy EM; O'Toole MG; Trent JO
Biochim Biophys Acta Gen Subj; 2017 May; 1861(5 Pt B):1414-1428. PubMed ID: 28007579
[TBL] [Abstract][Full Text] [Related]
17. Nucleolin inhibitor GroA triggers reduction in epidermal growth factor receptor activation: Pharmacological implication for glial scarring after spinal cord injury.
Goldshmit Y; Schokoroy Trangle S; Afergan F; Iram T; Pinkas-Kramarski R
J Neurochem; 2016 Sep; 138(6):845-58. PubMed ID: 27399849
[TBL] [Abstract][Full Text] [Related]
18. Tumor targeting with a (99m)Tc-labeled AS1411 aptamer in prostate tumor cells.
Noaparast Z; Hosseinimehr SJ; Piramoon M; Abedi SM
J Drug Target; 2015; 23(6):497-505. PubMed ID: 25673264
[TBL] [Abstract][Full Text] [Related]
19. Nucleolin-targeted Extracellular Vesicles as a Versatile Platform for Biologics Delivery to Breast Cancer.
Wang Y; Chen X; Tian B; Liu J; Yang L; Zeng L; Chen T; Hong A; Wang X
Theranostics; 2017; 7(5):1360-1372. PubMed ID: 28435471
[TBL] [Abstract][Full Text] [Related]
20. AGRO100 inhibits activation of nuclear factor-kappaB (NF-kappaB) by forming a complex with NF-kappaB essential modulator (NEMO) and nucleolin.
Girvan AC; Teng Y; Casson LK; Thomas SD; Jüliger S; Ball MW; Klein JB; Pierce WM; Barve SS; Bates PJ
Mol Cancer Ther; 2006 Jul; 5(7):1790-9. PubMed ID: 16891465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]